Hematologic Malignancies

ASH 2023

Questions discussed in this category

What are your top takeaways from ASH 2023?

7 Answers available

Papers discussed in this category

N. Engl. J. Med.,

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med,

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Blood, 2009 Mar 10

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 01

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

The New England journal of medicine, 2023 Dec 12

Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

Related Topics in Hematologic Malignancies